Literature DB >> 6512038

Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes.

R L Barnhill, N J Doll, L E Millikan, R C Hastings.   

Abstract

The effects of thalidomide on polymorphonuclear leukocyte (PMN) and monocyte function were studied in vitro. Phagocytosis of latex beads by both PMNs and adherent monocytes was significantly depressed (p less than 0.01) after a 1-hour incubation of cells with 10 microgram/ml of thalidomide. Concentrations of 1 microgram/ml stimulated monocyte phagocytosis (p less than 0.01) but did not influence PMNs. Incubation of monocytes with 10 micrograms/ml resulted in a significant reduction of chemiluminescence (CL) but had no effect at 1 microgram/ml concentrations. There was no significant action on PMN CL at either concentration. Finally, 10 micrograms/ml concentrations of thalidomide were not cytotoxic for either cell type after 18-hour incubations. In conclusion, the results of these studies may at least partially explain the efficacy of thalidomide in some inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6512038     DOI: 10.1016/s0190-9622(84)80458-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells

Authors:  Mahdieh Salemi; Saeed Mohammadi; Ardeshir Ghavamzadeh; Mohsen Nikbakht
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

2.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures.

Authors:  S M McHugh; I R Rifkin; J Deighton; A B Wilson; P J Lachmann; C M Lockwood; P W Ewan
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

3.  Integrated pathways for neutrophil recruitment and inflammation in leprosy.

Authors:  Delphine J Lee; Huiying Li; Maria T Ochoa; Motoyuki Tanaka; Ryan J Carbone; Robert Damoiseaux; Anne Burdick; Euzenir N Sarno; Thomas H Rea; Robert L Modlin
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

4.  The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats.

Authors:  Juan P Cata; Han-Rong Weng; Patrick M Dougherty
Journal:  Brain Res       Date:  2008-07-09       Impact factor: 3.252

5.  Thalidomide: an emerging drug in oral mucosal lesions.

Authors:  K Mubeen; M Ahmed Siddiq; V R Jigna
Journal:  Clin J Gastroenterol       Date:  2009-06-02

Review 6.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 7.  Role of innate immunity in chemotherapy-induced peripheral neuropathy.

Authors:  Megan L Uhelski; Yan Li; Miriam M Fonseca; E Alfonso Romero-Snadoval; Patrick M Dougherty
Journal:  Neurosci Lett       Date:  2021-05-04       Impact factor: 3.197

8.  Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.

Authors:  Elisabetta Buscarini; Luisa Maria Botella; Urban Geisthoff; Anette D Kjeldsen; Hans Jurgen Mager; Fabio Pagella; Patrizia Suppressa; Roberto Zarrabeitia; Sophie Dupuis-Girod; Claire L Shovlin
Journal:  Orphanet J Rare Dis       Date:  2019-02-04       Impact factor: 4.123

9.  Arsenic Trioxide and Thalidomide Combination Induces Autophagy Along with Apoptosis in Acute Myeloid Cell Lines.

Authors:  Mahnaz Mohammadi Kian; Atousa Haghi; Mahdieh Salami; Bahram Chahardouli; S Hahrbanoo Rostami; Kianoosh Malekzadeh; Hosein Kamranzadeh Foumani; Saeed Mohammadi; Mohsen Nikbakht
Journal:  Cell J       Date:  2019-10-14       Impact factor: 3.128

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.